{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:09:31Z","timestamp":1778836171784,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To describe the real-world outcomes of photodynamic therapy (PDT) as a rescue therapy in eyes with polypoidal choroidal vasculopathy (PCV) refractory to anti-vascular endothelial growth factor (VEGF) monotherapy in a British cohort of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a retrospective chart review of 53 eyes with PCV. Based on the timing of PDT, the eyes were stratified into two groups (9 in the Initial-PDT group, 44 in the Deferred group). The number of anti-VEGF injections\/year and the best corrected visual acuity (BCVA) before and after PDT were analysed. Multivariate regression model was created to identify factors predictive of visual outcome and treatment burden after PDT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The Deferred group received a mean of 9.4 injections\/year but significantly reduced to 7.2 after PDT (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The Initial-PDT group required significantly fewer injections after PDT compared to the Deferred group (<jats:italic>p<\/jats:italic>\u2009=\u20090.004). The Deferred group experienced improvement in BCVA from 58.7 letters at baseline to 63.8 at 18-months follow-up (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), but no significant increase was observed in the Initial-PDT group (<jats:italic>p<\/jats:italic>\u2009=\u20090.310). Better baseline BCVA is associated with higher likelihood of achieving good BCVA\u2009\u2265\u200970 letters after PDT (Odd Ratio=1.12, 95% CI: 1.03\u20131.21, <jats:italic>p<\/jats:italic>\u2009=\u20090.006), while increased number of anti-VEGF injections\/year before PDT reduces the likelihood of easing treatment burden to \u226512 weeks apart between each injection after PDT (Odd Ratio=0.724, 95% CI: 0.58\u20130.91, <jats:italic>p<\/jats:italic>\u2009=\u20090.006).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PDT as a rescue therapy is beneficial in the long-term management of PCV, particularly in eyes that had experienced a significant period of prior exposure to anti-VEGF monotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41433-021-01773-x","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T15:58:59Z","timestamp":1632844739000},"page":"1934-1939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-world outcomes of combined therapy of photodynamic therapy with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2684-4212","authenticated-orcid":false,"given":"Siyin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramandeep","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"1773_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","volume":"29","author":"A Laude","year":"2010","unstructured":"Laude A, Cackett PD, Vithana EN, Yeo IY, Wong D, Koh AH, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retinal Eye Res. 2010;29:19\u201329.","journal-title":"Prog Retinal Eye Res"},{"key":"1773_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","volume":"53","author":"CW Wong","year":"2016","unstructured":"Wong CW, Yanagi Y, Lee W-K, Ogura Y, Yeo I, Wong TY, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107\u201339.","journal-title":"Prog Retin Eye Res"},{"key":"1773_CR3","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1097\/IAE.0000000000001872","volume":"38","author":"TD Lorentzen","year":"2018","unstructured":"Lorentzen TD, Subhi Y, S\u00f8rensen TL. Prevalence of polypoidal choroidal vasculopathy in white patients with exudative age-related macular degeneration: systematic review and meta-analysis. Retina 2018;38:2363\u201371.","journal-title":"Retina"},{"key":"1773_CR4","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1136\/bjophthalmol-2016-310074","volume":"101","author":"S Yadav","year":"2017","unstructured":"Yadav S, Parry DG, Beare NAV, Pearce IA. Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians. Br J Ophthalmol. 2017;101:1377\u201380.","journal-title":"Br J Ophthalmol"},{"key":"1773_CR5","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen L-J, Chen S-J, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453\u201364.","journal-title":"Retina."},{"key":"1773_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","volume":"37","author":"P Nowak-Sliwinska","year":"2013","unstructured":"Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh AHC. Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res. 2013;37:182\u201399.","journal-title":"Prog Retin Eye Res"},{"key":"1773_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"1773_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ophtha.2013.12.037","volume":"121","author":"A Oishi","year":"2014","unstructured":"Oishi A, Miyamoto N, Mandai M, Honda S, Matsuoka T, Oh H, et al. LAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathy. Ophthalmology 2014;121:1151\u20132.","journal-title":"Ophthalmology"},{"key":"1773_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen S-J, Wong TY, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136:786\u201393.","journal-title":"JAMA Ophthalmol"},{"key":"1773_CR10","doi-asserted-by":"crossref","unstructured":"Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J, et al. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. BMC Ophthalmol [Internet]. 2016 Jul 27 [cited 2021 Apr 20];16. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4964097\/","DOI":"10.1186\/s12886-016-0305-2"},{"key":"1773_CR11","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/s41433-018-0168-2","volume":"32","author":"EI Agorogiannis","year":"2018","unstructured":"Agorogiannis EI, Pearce IA, Yadav S, Parry DG, Beare NAV. Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy. Eye (Lond). 2018 32:1731\u20139.","journal-title":"Eye (Lond)"},{"issue":"Sep 1","key":"1773_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","volume":"138","author":"TH Lim","year":"2020","unstructured":"Lim TH, Lai TYY, Takahashi K, Wong TY, Chen L-J, Ruamviboonsuk P, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138(Sep 1):935.","journal-title":"JAMA Ophthalmol"},{"key":"1773_CR13","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1097\/IAE.0000000000000206","volume":"34","author":"SJ Davis","year":"2014","unstructured":"Davis SJ, Lauer AK, Flaxel CJ. Polypoidal choroidal vasculopathy in white patients. Retina 2014;34:2185\u201391.","journal-title":"Retina"},{"key":"1773_CR14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/bjophthalmol-2013-303444","volume":"98","author":"K Hatz","year":"2014","unstructured":"Hatz K, Pr\u00fcnte C. Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol. 2014;98:188\u201394.","journal-title":"Br J Ophthalmol"},{"key":"1773_CR15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1136\/bjophthalmol-2014-305674","volume":"99","author":"CS Tan","year":"2015","unstructured":"Tan CS, Ngo WK, Chen JP, Tan NW, Lim TH, EVEREST Study Group. EVEREST study report 2: imaging and grading protocol, and baseline characteristics of a randomised controlled trial of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99:624\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1773_CR16","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","volume":"35","author":"F Gomi","year":"2015","unstructured":"Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: The Fujisan Study. Retina 2015;35:1569\u201376.","journal-title":"Retina"},{"key":"1773_CR17","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.2147\/OPTH.S178228","volume":"12","author":"M Ratanasukon","year":"2018","unstructured":"Ratanasukon M, Bhurayanontachai P, Jirarattanasopa P. Polypoidal choroidal vasculopathy (PCV): the 4-year review of the real-life treatment experiences. Clin Ophthalmol. 2018;12:2177\u201381.","journal-title":"Clin Ophthalmol"},{"key":"1773_CR18","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ophtha.2015.05.024","volume":"122","author":"A Yamamoto","year":"2015","unstructured":"Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, et al. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology 2015;122:1866\u201372.","journal-title":"Ophthalmology"},{"key":"1773_CR19","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ajo.2015.01.018","volume":"159","author":"A Oishi","year":"2015","unstructured":"Oishi A, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Nakanishi H, et al. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015;159:853\u2013860.e1.","journal-title":"Am J Ophthalmol"},{"key":"1773_CR20","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.ophtha.2012.02.002","volume":"119","author":"M Larsen","year":"2012","unstructured":"Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012;119:992\u20131000.","journal-title":"Ophthalmology"},{"key":"1773_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/IAE.0b013e3181fecda9","volume":"31","author":"T Hikichi","year":"2011","unstructured":"Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka S, et al. Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy. Retina 2011;31:857\u201365.","journal-title":"Retina"},{"key":"1773_CR22","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/eye.2014.222","volume":"28","author":"M Ho","year":"2014","unstructured":"Ho M, Lo ECF, Young AL, Liu DTL. Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome. Eye (Lond). 2014;28:1469\u201376.","journal-title":"Eye (Lond)"},{"key":"1773_CR23","first-page":"403","volume":"4","author":"BJ Fenner","year":"2020","unstructured":"Fenner BJ, Ting DSW, Tan ACS, Teo K, Chan CM, Mathur R, et al. Real-world treatment outcomes of age-related macular degeneration and polypoidal choroidal vasculopathy in asians. ophthalmology. Retina. 2020;4:403\u201314.","journal-title":"Retina."},{"key":"1773_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","volume":"128","author":"CMG Cheung","year":"2021","unstructured":"Cheung CMG, Lai TYY, Teo K, Ruamviboonsuk P, Chen S-J, Kim JE, et al. Polypoidal choroidal vasculopathy: consensus nomenclature and non\u2013indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup. Ophthalmology. 2021;128:443\u201352.","journal-title":"Ophthalmology."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01773-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01773-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T16:15:15Z","timestamp":1663863315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01773-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1773"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01773-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"17 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}